Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Safety, Tolerability and Efficacy of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism

ClinicalTrials.gov ID: NCT01254565

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT01254565. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 20, 2026, 11:01 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Double-Blind, Randomized, Placebo-Controlled Multiple Ascending Dose Study to Assess the Safety, Tolerability and Efficacy of KAI-4169 in Hemodialysis Subjects With Secondary Hyperparathyroidism

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to characterize the safety and tolerability and efficacy of multiple ascending doses of etelcalcetide in hemodialysis patients for the treatment of secondary hyperparathyroidism (HPT).

Study identification

NCT ID
NCT01254565
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
KAI Pharmaceuticals
Industry
Enrollment
87 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 20, 2011 (Type not available)
Primary completion
Jul 2011 (Actual)
Completion
Aug 24, 2011 (Actual)
Last update posted
Apr 13, 2017

2011

United States locations

U.S. sites
13
U.S. states
8
U.S. cities
12
Facility City State ZIP Site status
Not listed Azusa California 91702 —
Not listed Costa Mesa California 92626 —
Not listed Lynwood California 90262 —
Not listed Riverside California 92505 —
Not listed San Diego California 92123 —
Not listed Denver Colorado 80218 —
Not listed Macon Georgia 31217 —
Not listed Shreveport Louisiana 71101 —
Not listed Brooklyn Center Minnesota 55430 —
Not listed Philadelphia Pennsylvania 19106 —
Not listed Houston Texas 77004 —
Not listed Houston Texas 77099 —
Not listed Chesapeake Virginia 23320 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01254565, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 13, 2017 · Synced Nov 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.